Observational Approaches In Chronic Diseases
The number of innovative new drugs in chronic diseases has increased significantly to cope with the growing burden of these diseases, with sometimes questionable evidence bases. Some safety issues are detected after the introduction on the market through population studies that can be judiciously balanced with a comprehensive overview of the evidence to adequately redefine the benefit/risk balance of these new drugs.
Observational Approaches In The Elderly
Benefit-risk balance of the treatment of elderly people with neuropsychiatric disorders:
Epilepsy is the second most frequent neurological pathology in France. The prevalence of epilepsy is particularly high in the elderly, particularly due to comorbidities such as stroke.
Tolerance of duloxetine in the elderly:
Meta-analysis of individual patient data is an appropriate tool to explore the specific benefits and risks of drugs in vulnerable populations such as the elderly. Duloxetine has a wide range of approval in the elderly population (e.g. major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, stress urinary incontinence, etc.) but its safety in this vulnerable population does not is not clearly assessed. The aim is to explore the safety of duloxetine use in older people compared to younger adults.
